Therapeutic Potential of Natural Plant-Derived Compounds in Glioblastoma and Other Brain Tumors

Dear Colleagues,

Glioblastoma remains one of the most lethal and treatment-resistant cancers, largely due to its profound intratumoral heterogeneity, invasive nature, and the presence of the blood–brain barrier, which limits drug penetration. Current standard therapies, including surgery, radiation, and temozolomide, offer only modest survival benefits, with the 5-year survival rate remaining below 10%. Natural plant-derived compounds—such as flavonoids, alkaloids, terpenes, and polyphenols—have emerged as promising candidates for targeting glioblastoma and other brain tumors through diverse mechanisms, including induction of apoptosis, inhibition of proliferation, suppression of angiogenesis, and modulation of drug resistance pathways. Advances in nanoformulations and prodrug design are also enabling improved targeting and brain bioavailability of these compounds.

For this Special Issue, we invite original research articles and reviews focusing on the role of plant-derived natural compounds in glioblastoma and other brain tumors. Relevant topics include mechanistic studies of phytochemicals that influence tumor signaling, resistance pathways, glioma stem cell plasticity, and therapeutic synergy with existing treatments. We also welcome research exploring pharmacokinetics, novel delivery systems for improved brain targeting, and the modulation of tumor metabolism and the tumor microenvironment by dietary or plant-based compounds.

Dr. Agnieszka Nowacka
Dr. Ewa Aleksandra Ziółkowska
Dr. Daniela De Vita
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.